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in any medium, provided the original work is properly citeSeveral pathological processes, such as sepsis and inflammatory bowel disease
(IBD), are associated with impairment of intestinal epithelial barrier. Here, we
investigated the role of matrix metalloproteinase MMP13 in these diseases. We
observed that MMP13/ mice display a strong protection in LPS- and caecal
ligation and puncture-induced sepsis. We could attribute this protection to
reduced LPS-induced goblet cell depletion, endoplasmic reticulum stress,
permeability and tight junction destabilization in the gut of MMP13/ mice
compared to MMP13þ/þmice. Both in vitro and in vivo, we found that MMP13 is
able to cleave pro-TNF into bioactive TNF. By LC-MS/MS, we identified three
MMP13 cleavage sites, which proves that MMP13 is an alternative TNF
sheddase next to the TNF converting enzyme TACE. Similarly, we found that the
same mechanism was responsible for the observed protection of the MMP13/
mice in a mouse model of DSS-induced colitis. We identified MMP13 as an
important mediator in sepsis and IBD via the shedding of TNF. Hence, we propose
MMP13 as a novel drug target for diseases inwhich damage to the gut is essential.INTRODUCTION
Matrix metalloproteinases (MMPs) are important mediators
during the process of inﬂammation and are consequently
involved in several pathological processes, such as cancer
(Decock et al, 2011; Overall & Lopez‐Otin, 2002), sepsis
(Vandenbroucke et al, 2011a, 2012; Vanlaere & Libert, 2009),
lung diseases (Vandenbroucke et al, 2011b), ischaemia/
reperfusion (Dejonckheere et al, 2011) and arthritis (Burrage
et al, 2006). They constitute a group of structurally and
functionally related zinc‐dependent endopeptidases responsible, Ghent, Belgium
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d.for cleaving and rebuilding connective tissue components such
as collagen, elastin, gelatin and casein (Zitka et al, 2010).
Moreover, several extracellular and intracellular non‐matrix
substrates of MMPs have been identiﬁed, including chemokines,
cytokines, growth factors, junction proteins, molecular chaper-
ones and cytoskeletal proteins (Cauwe & Opdenakker, 2010;
Cauwe et al, 2007).
MMP13 (collagenase‐3) belongs to the family of collagenases
together with MMP1 and MMP8. Matrix substrates of MMP13
include native collagen, gelatin and aggrecan and non‐matrix
substrates include MCP‐3 and pro‐MMP9. MMP13 activity in
chondrocytes and synovial cells appears to be critical in cartilage
formation and in joint diseases (Takaishi et al, 2008). MMP13
has also been implicated in tumour invasion and metastasis
(Fukuda et al, 2011; Wu et al, 2012), lung diseases (Shukla
et al, 2006), and periodontal disease (de Aquino et al, 2009).
Additionally, some reports suggest that MMP13 is important in
IBD, an umbrella term that includes Crohn’s disease and
ulcerative colitis (UC), two chronic relapsing inﬂammatory
disorders of the gut. Signiﬁcantly increased levels of MMP13
mRNA were found in IBD biopsy specimens (Rath et al, 2006).s is an open access article under
se, distribution and reproduction
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Figure 1. MMP13 deﬁciency protects mice from LPS‐induced systemic inﬂammation and lethality.
A–D. MMP13 gene expression analysis in ileum (A), liver (B) lung (C), and kidney (D) 0, 1, 4, 6, 8, and 12 h after LPS challenge (n ¼ 5).
E–F. Body temperature (E) and survival (F) of MMP13þ/þ (black) and MMP13/ (grey) mice after LPS injection (i.p.; 17.5 mg/kg) (n ¼ 15).
G. Survival of MMP13þ/þ (black; n ¼ 7) and MMP13/ (grey; n ¼ 12) mice after CLP.
H–K. Serum cytokine and chemokine levels after injection of LPS in MMP13þ/þ (black) and MMP13/ (grey) mice: IL1b (H), TNF (I), IL17 (J) and MCP1 (K) (n ¼ 4–5).
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expression and the histological inﬂammation scores in mucosal
samples from IBD patients (Vizoso et al, 2006). Recently, both
endothelial cells and inﬁltrating leucocytes were identiﬁed as the
major sources of MMP13 in UC (Rath et al, 2010).
IBD, as well as other pathological events such as sepsis, are
associated with impairment of the intestinal epithelial barrier
(John et al, 2011; Turner, 2009). Consequently, intestinal lumen
components (i.e., bacteria, PAMPs and alarmins) leak into
the bloodstream, inducing a systemic inﬂammatory response
syndrome (SIRS), which can result in lethal multi‐organ failure
(Balzan et al, 2007). Tight junctions play an important role in
the formation and maintenance of the intestinal epithelial
barrier, as they tightly seal adjacent intestinal epithelial cells
(IECs) at the apical site (Farquhar & Palade, 1963). Tight
junctions transmembrane proteins such as occludin and
claudins mediate adhesion by linkage to the underlying plaque
proteins, which in turn associate with the cytoskeleton.
Examples of plaque proteins are zona occludens (ZO) 1, 2
and 3 (Niessen, 2007). Several papers have reported that
MMPs play a direct or indirect role in increasing epithelial barrier
permeability (Ailenberg & Sefton, 2009; Huet et al, 2011;
Vandenbroucke et al, 2012).EMBO Mol Med (2013) 5, 932–948 In this study, we investigated whether MMP13 plays a role in
epithelial barrier disruption during pathological events such as
sepsis and IBD, by using endotoxemia and DSS‐induced colitis
models, respectively. We found that MMP13 contributes to
intestinal permeability by causing TNF shedding, which
increases the levels of soluble, bioactive TNF. Consequently,
TNF induces endoplasmic reticulum (ER) stress mediatedmucus
depletion in the gut, increased intestinal inﬂammation, reduced
functionality of the tight junctions, and increased intestinal
permeability. These changes lead to leakage of luminal
components into the periphery, systemic inﬂammation, organ
damage and eventually death. In conclusion, our results suggest
that MMP13 is a potential therapeutic target for treatment of
inﬂammatory disorders associated with TNF‐dependent dys-
function of the intestinal barrier, such as sepsis and IBD.RESULTS
MMP13 deﬁciency protects mice from LPS‐induced systemic
inﬂammation and lethality
To investigate whether MMP13 contributes to the lethal effects
of sepsis, we compared the response of wild type (MMP13þ/þ)2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 933
Figure 2.
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model, i.e., i.p. injection of LPS, a model of human sepsis
(Cantaluppi et al, 2008; Cruz et al, 2007, 2009). Early after
endotoxemia induction, we observed strong up‐regulation of
MMP13 in all tested organs (Fig 1A–D). MMP13/ mice were
signiﬁcantly protected against LPS‐induced hypothermia
(Fig 1E) and death (Fig 1F). We also subjected MMP13þ/þ
and MMP13/ mice to caecal ligation and puncture (CLP), the
gold standard model for human sepsis (Dejager et al, 2011), and
this revealed that MMP13/ mice are also signiﬁcantly
protected against CLP‐induced death (Fig 1G). Next, we studied
the cyto‐ and chemokine levels in sera of LPS‐injected mice. We
observed substantial differences in the absolute concentrations,
time courses and clearance of the tested cyto‐ and chemokines.
Most inﬂammatory mediators reached their maximum around
6–12 h, with the exception of TNF, which reached a peak after
1 h, followed by a rapid decline (Fig 1H–K and Supporting
Information Fig S1). We observed that 12 h after LPS injection,
all cytokines (IL1b, IL6, IL10, IL12p40, IL12p70, IL17 and IFN‐g)
and chemokines (G‐CSF, GM‐CSF, KC, MCP1 and Rantes) were
lower in MMP13/ mice than in MMP13þ/þ mice. Moreover,
serum levels of IL1b (Fig 1G), TNF (Fig 1H), IL17 (Fig 1I) and
MCP1 (Fig 1J) were lower even at the earlier time points after
challenge in MMP13/ mice. These results indicate that
MMP13 plays a detrimental role in sepsis‐induced systemic
inﬂammation and lethality.
MMP13 deﬁciency protects mice from LPS‐induced intestinal
permeability, mucus depletion and ER stress
The ‘gut as motor of sepsis’ hypothesis has been postulated
based on the importance of the intestinal epithelium as a
physical barrier between the intestinal lumen and the immune
cells in the lamina propria (Carrico et al, 1986; Deitch &
Berg, 1987). Indeed, in critically ill sepsis patients, intestinal
permeability is correlated with bacterial translocation and
subsequent multi‐organ failure (Faries et al, 1998; Swank &
Deitch, 1996).
We ﬁrst addressed which cell type in the ileum is responsible
for MMP13 expression. Immunostaining revealed MMP13Figure 2. MMP13 deﬁciency protects mice from LPS‐induced intestinal perm
A,B. Representative confocal images of MMP13 (red) and DAPI (blue) immunost
C. C.Intestinal permeability in MMP13þ/þ (black) and MMP13/ (grey) mice
administered orally to the mice and 5 h later plasma was collected and flu
D,E. Representative hematoxylin and eosin stained sections of the ileum of MMP1
of epithelial cells and cell debris in the lumen is indicated with an arrow.
F. Quantification of intestinal tissue damage in MMP13þ/þ (black) and MMP1
hematoxylin and eosin (n ¼ 5) in a blinded setup. LPS-induced intestinal dam
layer and goblet cells along the villus, cell death at the villus top, and cell
G–I Goblet cell amount (G) and size distribution (H-I) in MMP13þ/þ (black; H) and
insert displays a representative image of Alcian blue stained ileal sections
J. Survival ofMMP13þ/þmice (black) andMMP13þ/þmice pretreatedwith them
in MMP13þ/þ) (n ¼ 5).
K. Survival of LPS-injected (i.p.; 17.5 mg/kg; LD0 in MMP13/mice) untreated
L,M. Representative morphological TEM images of MMP13þ/þ (L) and MMP13/
N. mRNA expression analysis of spliced Xbp-1 (sXbp-1) in ileum lysates of MM
O,P. Representative confocal images of BiP (red) and DAPI (blue) immunosta
injection.
EMBO Mol Med (2013) 5, 932–948 expression both in epithelial and inﬂammatory cells (Fig 2A).
Four hours of LPS stimulation resulted in decreased MMP13
staining in the epithelial cells at the top of the villi, which
suggests LPS‐induced MMP13 secretion, while MMP13 expres-
sion in the inﬂammatory cells in the lamina propria increased
further after LPS injection (Fig 2B).
To exclude compensation by other MMPs in the ileum of
MMP13/mice, we analysed MMP expression in ileum lysates.
None of the tested MMPs were up‐regulated, except MMP3
which displayed a two‐fold down‐regulation in MMP13/
lysates when compared to MMP13þ/þ mice (Supporting
Information Fig S2).
To study intestinal leakage in MMP13þ/þ and MMP13/
mice after LPS challenge, ﬂuorescently labeled FITC‐dextranwas
administered orally to the mice. We observed an increase of
ﬂuorescence in plasma of LPS‐treated MMP13þ/þmice, which is
a measure of leakage from the intestinal lumen into the
peripheral blood (Fig 2C). In contrast, MMP13/ mice did not
suffer from increased intestinal permeability. Despite the
difference in intestinal permeability, morphological analysis
revealed similar intestinal damage inMMP13þ/þ andMMP13/
mice after LPS challenge (Fig 2D–F). Similarly, TUNEL staining
showed equal levels of apoptosis induction in MMP13þ/þ and
MMP13/ mice (Supporting Information Fig S3). However,
detailed analysis of the goblet cells by Alcian blue and MUC2
staining did reveal important differences both in the amount and
size of Alcian blue positive goblet cells early after LPS challenge.
Fig 2G shows that LPS reduces the amount of Alcian blue
positive goblet cells in MMP13þ/þ mice, but not in MMP13/
mice. Additionally, size distribution analysis shows that the
percentage of goblet cells with reduced mucus content increases
substantially in MMP13þ/þ mice 4 h after LPS challenge,
whereas size distribution was unaffected in MMP13/ mice
(Fig 2H–I). Those observations were further conﬁrmed byMUC2
immunostaining, both at 4 and 24 h (Supporting Information Fig
S4). Treatment with pilocarpine, a mucus depleting agent
(Albanese et al, 1994), sensitized both MMP13þ/þ (Fig 2J) and
MMP13/ (Fig 2K) mice to endotoxemia, pointing towards a
crucial role of mucus in the protection against sepsis. Moreeability, mucus depletion and ER stress.
aining of unstimulated (A) and LPS-stimulated (B) (4 h) ileum sections.
0, 8 and 20 h after LPS injection. Fluorescently labeled FITC-dextran was
orescence was measured.
3þ/þ (D) and MMP13/ (E) 8 h after LPS injection. Bar ¼ 50 mm. The presence
3/ (grey) mice: four neutral observers evaluated ileal sections stained with
age is characterized by decreased villus height, disappearance of the mucus
debris in the lumen.
MMP13/ (grey; I) mice 0 (blank) and 4 h (hatched) after LPS injection. The
of MMP13þ/þ (H) and MMP13/ (I) mice. Bar ¼ 50 mm.
ucus depleting agent pilocarpine (grey) after LPS injection (i.p.; 6 mg/kg; LD50
(square; n ¼ 4) and pilocarpine treated (circle; n ¼ 3) MMP13/mice (grey).
 (M) mice 8 h after LPS injection. The insert is a close-up of the ER.
P13þ/þ (black) and MMP13/ (grey) 8 h after LPS injection (n ¼ 5).
ining of MMP13þ/þ (O) and MMP13/ (P) ileum sections 8 h after LPS
2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 935
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936detailed analysis of goblet cell morphology by transmission
electron microscopy (TEM) revealed that the ER of wild type
goblet cells was dilated after LPS challenge (Fig 2L). This was not
the case in MMP13/mice (Fig 2M). Additionally, two markers
for ER stress, namely spliced Xbp1 (sXbp1) mRNA (Fig 2N) and
BiP protein (Fig 2O–P) were higher in LPS‐stimulatedMMP13þ/þ
compared to MMP13/ mice. These results show that MMP13
deﬁciency protects from LPS‐induced intestinal permeability,
mucus depletion and goblet cell ER stress after systemic LPS
injection.
MMP13 contributes to tight junction destabilization
Intercellular junctions, such as tight junctions, play a crucial role
in the formation and maintenance of the intestinal epithelial
barrier. Consequently, intestinal permeability is often linked to
tight junction malfunctioning (John et al, 2011). Several MMPs
have been shown to cleave the components of tight junctions,
thereby inﬂuencing their functionality. For example, it has been
reported that hypoxia‐inducedMMP13 results in disorganization
and fragmentation of the intracellular tight junction scaffolding
protein ZO‐1 (zona occludens), which results in hyperpermea-
blility of the blood–brain barrier (Lu et al, 2009). Western blot
analysis of intestinal mucosal scrapings showed that LPS did not
induce a decrease in the amount of full length ZO‐1 protein
(Fig 3A). Similar results were obtained for occludin (Fig 3B) and
claudin‐1 (Fig 3C). However, IEM analysis did reveal severe
differences in the amount of immunogold‐labeled ZO‐1 located
at the apical tight junctions: after LPS challenge, much more
tight junction‐localized ZO‐1 could be detected in the IECs of
MMP13/mice compared to MMP13þ/þmice (Fig 3D–E). This
observation was conﬁrmed by immunoﬂuorescent ZO‐1 staining
(Supporting Information Fig S5). Apparently, although total ZO‐1
protein levels were equal in MMP13þ/þ and MMP13/ mice,
therewas a profound difference in localization after LPS challenge.
Tight junctions are part of specialized lipid raft‐likemembrane
microdomains (Nusrat et al, 2000). It was recently shown that
sepsis causes redistribution of tight junctions in membrane
microdomains and that this redistribution is responsible for
increased permeability (Li et al, 2009). Mucosal scrapings from
the ileum were homogenized and separated by ultracentrifuga-
tion. As shown in Fig 3F, after ultracentrifugation, the upper
fractions contain the lipid rafts and the lower fractions the non‐
lipid rafts. Comparison of mucosal scrapings from the ilea of
challenged MMP13þ/þ and MMP13/ mice revealed that
caveolin‐1, an essential molecule in lipid raft microdomains,
was present in different fractions. In LPS‐treated MMP13/
mice, caveolin‐1 was in the lipid raft fraction, but it shifted
almost completely to the non‐lipid‐raft fraction in the LPS‐
treated MMP13þ/þ mice (Fig 3G). This indicates that MMP13
deﬁciency protects from LPS‐induced tight junction redistribu-
tion and therefrom resulting increased intestinal permeability.
MMP13 cleaves proTNF, resulting in the formation of mature,
bioactive TNF
Marchiando et al. recently showed that TNF induces caveolin‐1‐
dependent endocytosis of tight junction proteins, which results
in increased intestinal permeability (Marchiando et al, 2010). 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.TNF is translated as a 26‐kDa transmembrane precursor protein
(tmTNF) that is proteolytically cleaved to release the soluble and
biologically active 17‐kDa C‐terminal part (soluble TNF; sTNF).
sTNF is known to induce a concentration‐ and time‐dependent
increase in epithelial permeability both in vitro and in vivo
(Gitter et al, 2000; He et al, 2012; Ma et al, 2004, 2005;
Marchiando et al, 2010; Schmitz et al, 1999). Although the major
sheddase responsible for proTNF cleavage is TACE (tumour
necrosis factor‐a‐converting enzyme; Adam17), Adam10 (Le
Gall et al, 2009) and MMP‐mediated shedding of TNF might also
be important (Overall & Blobel, 2007). Several MMPs were
shown to be able to cleave proTNF in vitro: MMP1, 2, 3, 7,
9,12,14 and15 (Chandler et al, 1996; d’Ortho et al, 1997;
Gearing et al, 1995; Tam et al, 2004).
To study whether MMP13 can cleave proTNF, the two
proteins were co‐incubated in vitro. As shown in Fig 4A and B,
MMP13 can cleave proTNF in vitro to generate different N‐
terminal TNF fragments (17, 15, 13 and 11 kDa).
Comparison of the TNF bioactivity revealed that 10 min co‐
incubation of proTNF with TACE or activated MMP13 (1:1 ratio)
results in 218 and 227 U/mg bioactive TNF, respectively. By LC‐
MS/MS analysis, we could identify three different MMP13
cleavage sites, namely S68, A90 and A111 (Fig 4C). To determine
if shedding of TNF is also dependent on MMP13 in vivo, we
analysed TNF bioactivity in ileal lysates from MMP13þ/þ and
MMP13/mice obtained 1 h after LPS challenge. Fig 4D shows
that TNF bioactivity was signiﬁcantly higher in ileum of
MMP13þ/þ mice, which suggests that MMP13 can also cleave
proTNF into soluble, bioactive TNF in vivo.
MMP13‐dependent TNF cleavage was further conﬁrmed both
in vitro and ex vivo. Primarymousemacrophages fromMMP13þ/
þmice were isolated by peritoneal lavage and stimulated in vitro
with LPS in the absence or presence of MMP13 inhibitor. As
shown in Fig 4E, MMP13 inhibition results in a decrease in TNF
release into the supernatant. Similarly, ileum explants of LPS
injected MMP13þ/þ mice were incubated ex vivo with different
concentrations of MMP13 inhibitor. This resulted in a dose
dependent decrease in TNF (Fig 4F).
If the LPS resistance of the MMP13/mice can be attributed
to TNF, one would expect that MMP13/ mice are as sensitive
to systemic TNF injection as MMP13þ/þ mice. Indeed, no
signiﬁcant difference in response of MMP13þ/þ and MMP13/
mice upon TNF injection could be detected (Fig 4G).
MMP13‐dependent intestinal TNF activation results in mucus
depletion and increased intestinal inﬂammation
TNF has been shown to induce mucus secretion (McElroy
et al, 2011), so the depletion of mucus observed in MMP13þ/þ
mice might be a direct effect of increased TNF levels. Indeed,
incubation with TNF in vitro resulted in goblet cell Muc2 gene
expression up‐regulation (Fig 5A) and TNF injection in vivo
resulted in a reduction of total goblet cell mucus (Fig 5B). The
latter was conﬁrmed by immunoﬂuorescent staining of intestinal
MUC2 before (Fig 5C) and after (Fig 5D) TNF injection. In the
absence of a proper mucus layer, intestinal bacteria can interact
with the underlying IECs (McGuckin et al, 2011). To address the
importance of intestinal bacteria in LPS‐induced shock, we ﬁrstEMBO Mol Med (2013) 5, 932–948
Figure 3. MMP13 contributes to tight junction destabilization. Source data is available for this figure in the Supporting Information.
A–C. Western blot quantification of the protein expression levels of ZO-1 (A), occludin (B) and claudin (C) in mucosal scrapings of ilea fromMMP13þ/þ (black) and
MMP13/ (grey) mice 0 and 8 h after LPS injection (n ¼ 3–4).
D,E. Representative ZO-1 immunogold-labeled TEM images of MMP13þ/þ (D) and MMP13/ (E) mice 8 h after LPS injection.
F. Schematic overview of the separation of the lipid raft and non-lipid-raft fractions by ultracentrifugation.
G. Caveolin-1 western blot analysis of fractions obtained after ultracentrifugation of mucosal scrapings from MMP13þ/þ and MMP13/mice 0 and 8 h after
LPS challenge.
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Figure 4. MMP13 cleaves proTNF to generate mature, bioactive TNF. Source data is available for this figure in the Supporting Information.
A. Silver staining of proTNF (47 kDa) andMMP13 (52 kDa) samples incubated at 37˚C for 0, 2, 5, 10, 20 and 30 min followed by SDS-PAGE. Anti-TNF western blot
analysis of co-incubated proTNF (47 kDa) and MMP13 (52 kDa) samples at 37˚C for 0, 2, 5, 10, 20 and 30 min with formation of mature TNF.
B. Anti-TNF western blot analysis of proTNF (47 kDa), incubated at 37˚C for 10 min with TACE and MMP13. Cleavage of proTNF by TACE results in two mature
TNF fragments (17 and 15 kDa; grey). Cleavage of proTNF by MMP13 results in four cleavage fragments (17, 15, 13 and 11 kDa).
C. Identified proTNF cleavage sites of MMP13 by LC-MS/MS (red arrow) and known TACE cleavage site (black arrow).
D. TNF bioactivity of ileal lysates of MMP13þ/þ (black) and MMP13/ (grey) mice 1 h after LPS injection (n ¼ 5).
E. TNF levels of in vitro LPS-stimulated MMP13þ/þ macrophages incubated in the absence or presence of MMP13 inhibitor.
F. TNF levels of ileum explants from in vivo LPS stimulated MMP13þ/þ mice incubated ex vivo with and without MMP13 inhibitor.
G. Survival of MMP13þ/þ (black) and MMP13/ (grey) mice injected with TNF (25 mg/20 g) (n ¼ 8).
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938treated wild type mice with antibiotics to remove all bacteria
from the gut. Next, we injected sterile and non‐sterile MMP13þ/þ
mice with LPS and analysed the effect on LPS lethality and IL‐6
levels. Fig 5E shows that sterile mice were protected against the
lethal effects of LPS. To address the importance of TNF in the
endotoxemia model, we treated mice with Etanercept that acts as
a TNF inhibitor (Kerensky et al, 2012). TNF inhibition resulted in
protection of the mice in terms of survival rate (Fig 5F), intestinal
permeability (Fig 5G) and amount of mucus containing goblet
cells (Fig 5H and I). Additionally, mice deﬁcient in the TNF
receptor TNFR1, which is implicated in TNF‐induced acute
toxicity (Van Hauwermeiren et al, 2011), were protected against
LPS‐induced lethality (Supporting Information Fig S6). 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.The absence of mucus can lead to increased interaction of
bacteria with the IECs (McGuckin et al, 2011). This, together
with elevated TNF levels, could induce epithelial cell inﬂamma-
tion. Indeed, we observed more intestinal inﬂammation in
MMP13þ/þmice than in MMP13/mice. LPS injection resulted
in strong up‐regulation of IL‐6 (Fig 5J) and iNOS (Fig 5K) in the
ileum of MMP13þ/þ mice. This up‐regulation was signiﬁcantly
lower in MMP13/ mice. Moreover, we observed increased
Paneth cell activation in MMP13þ/þ mice. This was reﬂected in
increased MMP7 (Fig 5L) and RegIIIg (Fig 5M) gene expression
levels after LPS challenge in MMP13þ/þ mice, while no
induction of Paneth‐speciﬁc genes was observed in MMP13/
mice.EMBO Mol Med (2013) 5, 932–948
Figure 5. MMP13‐dependent intestinal TNF activation results in mucus depletion, increased intestinal inﬂammation, systemic inﬂammation and organ
damage.
A. TNF (2000 U/ml) induces upregulation of Muc2 gene expression in goblet cells in vitro (n ¼ 6).
B. Quantification of total goblet cell mucus before and 8 h after TNF injection in vivo by Alcian blue staining of isolated ileum samples, followed by laxative
treatment and absorbance measurement of the supernatant (n ¼ 8).
C,D. Representative images of MUC2 (red) and DAPI (blue) immunostainings of ileal sections in the absence of TNF (C) and 8 h after TNF injection (D).
E. Survival curve of non-sterile (black) and sterile, antibiotics treated (grey) mice after LPS injection (i.v.; 250 mg/20 g) (n ¼ 12).
F,G. Survival curve (F) and intestinal permeability (G) of LPS-injectedMMP13þ/þmice pretreated with PBS (black; n ¼ 10) or anti-TNF (grey; n ¼ 3) (i.p.; 17.5 mg/kg).
H,I. Representative mucin-2 (red) confocal images of ileal sections of LPS-injected mice pretreated with PBS (H) and anti-TNF (I).
J,K. Gene expression analysis of IL6 and iNOS in ileum lysates of MMP13þ/þ (black) and MMP13/ (grey) mice 0 and 8 h after LPS injection (n ¼ 4–5).
L,M. Gene expression analysis of the Paneth-cell-specific genes MMP7 (H) and RegIIIg (I) in ileum lysates of MMP13þ/þ (black) and MMP13/ (grey) mice 0 and
8 h after LPS injection (n ¼ 4–5).
N. IL-FABP levels in serum of MMP13þ/þ (black) and MMP13/ (grey) mice 8 h after LPS injection (n ¼ 5–7).
O. Relative serum LDH activity 8 h after LPS injection in MMP13þ/þ (black) and MMP13/ (grey) mice (n ¼ 6–14).
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EMBO Mol Med (2013) 5, 932–948  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 939
Figure 6. MMP13 deﬁciency results in reduced clinical signs of DSS‐induced colitis.
A. Clinical score of MMP13þ/þ (black) and MMP13/ (grey) mice after 5 days of treatment with 2% DSS (n ¼ 12–14). Clinical scores are a composite of body
weight loss, rectal bleeding and stool consistency scores.
B. MMP13 gene expression before and 6 days after 2% DSS treatment.
C. Colon length of MMP13þ/þ (black) and MMP13/ (grey) mice on day 6 after the start of the DSS treatment (n ¼ 4).
D. TNF bioactivity of colon lysates of MMP13þ/þ (black) and MMP13/ (grey) mice 6 days after 2% DSS treatment (n ¼ 4; one-tailed t-test).
Research Article www.embomolmed.org
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940MMP13‐dependent intestinal leakage results in systemic
inﬂammation and multi‐organ failure
After LPS challenge, MMP13þ/þ mice, in contrast to MMP13/
mice, displayed an increase in intestinal permeability (Fig 2C).
This increased permeability can result in leakage of intestinal
lumen components into the periphery. Indeed, serum analysis of
LPS‐injected mice showed high ileal fatty acid‐binding protein
(IL‐FABP) levels in MMP13þ/þ mice (Fig 5N), a non‐invasive
marker for intestinal mucosal damage (Lieberman et al, 1997).
IL‐FABP levels were signiﬁcantly lower in MMP13/ mice.
Leakage of intestinal content into the periphery can induce a
further increase in systemic inﬂammation, which eventually
results in multi‐organ failure. Serum levels of lactate dehydro-
genase (LDH), a marker for general tissue damage, were below
detection limit in unchallenged mice (data not shown).
However, LDH levels were higher in MMP13þ/þ than in
MMP13/ mice 8 h after LPS challenge (Fig 5O), which
suggests multi‐organ failure in MMP13þ/þ, but not in MMP13/
mice.
MMP13 deﬁciency results in reduced signs of clinical colitis
after DSS treatment
Both TNF and MUC2 play a major role in the development of
DSS‐induced colitis via their involvement in epithelial barrier 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.function, and they are altered before epithelial cell damage
occurs (Dharmani et al, 2011). On the basis of our ﬁndings, we
hypothesized that the absence of MMP13 could be protective in
this colitis model. When MMP13þ/þ and MMP13/ mice were
given 2% DSS in the drinking water for 5 days, the knockout
mice showed milder disease in terms of weight loss, stool
consistency and rectal bleeding (Fig 6A). In agreement with this,
we observed a signiﬁcant increase in MMP13 gene expression
after DSS treatment (Fig 6B). The DSS‐induced model of colitis is
associated with a signiﬁcant decrease in colon length, and
evaluation of colon length is believed to be the least variable
parameter. Measurement of colon length in MMP13þ/þ and
MMP13/mice 6 days after the start of DSS treatment revealed
that MMP13 deﬁciency reduces the effect of DSS‐induced colitis
on the length of the colon (Fig 6C). Again, this was associated
with reduced TNF bioactivity in colon lysate (Fig 6D).DISCUSSION
The intestinal epithelium separates the intestinal lumen from the
underlying lamina propria and thereby provides an important
physical barrier against entry of luminal microbiota. Apical tight
junctions are multifunctional structures that form a seal betweenEMBO Mol Med (2013) 5, 932–948
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luminal material across the epithelium (Farquhar & Palade,
1963). Consequently, inﬂammation‐induced disruption of tight
junctions can contribute to leakage of luminal components into
the periphery (John et al, 2011). Intestinal epithelial dysfunction
is believed to be a common ﬁnal pathway contributing to organ
dysfunction and mortality in sepsis (Fink, 2003). In line with
this, we observed a huge increase in intestinal permeability and
IL‐FABP serum levels, a marker for intestinal damage, in
MMP13þ/þ mice after LPS challenge. This was associated with
high serum levels of cytokines, chemokines and LDH, the latter
being an indicator of general tissue damage. In contrast, LPS‐
injected MMP13/ mice maintained a functional epithelial
barrier and exhibited less severe systemic inﬂammation and
organ damage. Eventually, this results in survival of the
MMP13/ mice, while almost all MMP13þ/þ mice succumbed.
Similar protection was observed in the mouse model that is
considered as the ‘gold standard’ for sepsis research, namely
CLP (Dejager et al, 2011).
Both in vivo and in vitro studies have demonstrated that TNF
is one of the crucial factors involved in the pathogenesis of
intestinal permeability and that tight junction destabilization is
implicated in this process (Gitter et al, 2000; He et al, 2012; Ma
et al, 2004, 2005; Marchiando et al, 2010; Schmitz et al, 1999).
ProTNF is a transmembrane protein that is cleaved into soluble,
biological active TNF. Although TACE is the main sheddase
involved in this process, it is likely that TACE and MMPs have
complementary roles in the rapid shedding and activation of
proTNF in response to different stimuli (Overall & Blobel, 2007).
This idea is strengthened by the fact that TACE/ cells still
secrete 10–20% sTNF compared to TACEþ/þ cells (Killar
et al, 1999). Noncleavable transmembrane TNF transgenic mice
were fully protected from endotoxic shock, pointing towards the
importance of TNF cleavage in the endotoxemia model (Mueller
et al, 1999). Here, we clearly show that MMP13 can cleave and
activate proTNF in vitro and we could identify three cleavage
sites, one upstream and two downstream of the TACE cleavage
site, resulting in similar bioactivity. However, substrate
speciﬁcity of MMPs is partly regulated by their cellular
localization, which makes it dangerous to directly interpret
substrates identiﬁed in vitro as in vivo substrates. We detected
MMP13 expression in epithelial and inﬂammatory cells in the
ileum and conﬁrmed via several approaches that TNF is a direct
substrate of MMP13. In vivo, bioactive, soluble TNF levels were
higher in the inﬂamed tissue of MMP13þ/þ compared to
MMP13/ mice in LPS‐induced shock. Moreover, LPS stimula-
tion of both primary mouse macrophages and ileum explants
incubated with MMP13 inhibitor resulted in reduced TNF levels.
Additionally, MMP13þ/þ and MMP13/mice showed a similar
response upon systemic TNF injection. The latter indicates that
the resistance of the MMP13/ mice to LPS challenge can at
least partially be attributed to the MMP13‐dependent cleavage of
TNF. To exclude the involvement of other proteases that have
been described to cleave and activate TNF, we measured
Adam17 and ‐10 as well as MMP1, 2, 3, 7, 9, 12, 14
and 15 expression (Chandler et al, 1996; d’Ortho et al, 1997;
Gearing et al, 1995; Tam et al, 2004). Only MMP7 was signiﬁcantEMBO Mol Med (2013) 5, 932–948 higher expressed in LPS‐stimulated MMP13þ/þ mice compared
to MMP13/ mice. Consequently, it is possible that MMP7
contributes to the observed difference in TNF activation in
MMP13þ/þ mice. However, the fact that MMP13 inhibition
results in lower TNF levels, argues against this. Rather, this
difference in MMP7 expression is likely a reﬂection of the
increased Paneth cell activation, which is observed in the
MMP13þ/þ mice, which is a consequence of the observed LPS‐
induced mucus loss.
It was recently shown that TNF can affect tight junctions via
the induction caveolin‐dependent endocytosis of tight junction
proteins (Marchiando et al, 2010). In agreement with this, we
observed that caveolin‐1 translocated from the lipid raft to the
non‐lipid‐raft fraction after LPS challenge in MMP13þ/þ, but not
in MMP13/ mice. In addition, by IEM and immunoﬂuores-
cence, we observed severe effects of LPS on the subcellular
localization of ZO‐1, which is crucial for clustering of claudins
with the actin cytoskeleton, again only in the MMP13þ/þmice. It
is believed that ZO‐1 forms a direct link between actin and the
transmembrane tight junction proteins. Consequently, translo-
cation of ZO‐1 and thereby the associated contraction of
cytoskeletal actin is thought to play an important role in the
regulation of epithelial barrier function (Umeda et al, 2006). We
did not observe LPS‐dependent effects on the total protein level
of different tight junction proteins, such as ZO‐1, occludin and
claudin‐1, but it is known that it is mainly not the expression
level but the expression pattern of tight junction proteins that
determines epithelial permeability (Iwaya et al, 2012).
Not only the epithelial cell layer itself, but also the overlying
mucus barrier, which consists of large glycoproteins called
mucins, is extremely important for the intestinal barrier
function. This is underlined by the observation that mice
deﬁcient in Muc2, the most abundant mucin in the small
intestine, develop spontaneous intestinal inﬂammation (Van der
Sluis et al, 2006). In vitro, we observed a TNF‐dependent up‐
regulation of Muc2 gene expression in goblet cells, which is in
agreement with literature where it was described that incubation
of goblet cells with TNF induces mucin secretion within the ﬁrst
24 h (Smirnova et al, 2001). Additionally, TNF injection in vivo
resulted in a loss of goblet cells containingmucus, determined by
quantiﬁcation of total mucus and MUC2 immunoﬂuorescence.
This shows that TNF induces not only expression of mucus but
also its secretion, ﬁnally resulting in the depletion of mucus.
Indeed, we observed an LPS‐induced decrease in mucus in
MMP13þ/þ but not in MMP13/mice. The depletion of mucus
by pilocarpine treatment resulted in sensitization for LPS‐
induced shock both in MMP13þ/þ and MMP13/ mice, which
further strengthens the notion of the important role of the mucus
layer in endotoxemia. Recently, it was reported that spontaneous
mucus depletion inWinnie and Eeyoremice, created by random
mutagenesis of the Muc2 gene, was associated with ER stress
(Heazlewood et al, 2008). In agreement with this, we observed,
but only in MMP13þ/þ mice, LPS‐induced evidence of ER stress
in goblet cells (by TEM) and altered intestinal expression of
spliced Xbp1 and BiP, both of which are involved in ER stress
(Kaser et al, 2011). Disappearance of the mucus layer in
MMP13þ/þ mice allows the intestinal bacteria to interact with2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 941
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942IECs and Paneth cells, resulting in increased local inﬂammation
and activation of Paneth cells. In LPS‐injected MMP13þ/þ mice
this was reﬂected in up‐regulation of inﬂammatory genes, such
as IL6 and iNOS, and Paneth‐cell speciﬁc genes, such as RegIIIg
and MMP7. RegIIIg is an antibacterial agent present in the
Paneth cells induced by the commensal microbes (Wlodarska &
Finlay, 2010). The importance of the intestinal bacteria was
further strengthened by the observation that sterile MMP13þ/þ
mice were more resistant than non‐sterile MMP13þ/þ mice to
LPS‐induced shock.
Both TNF and mucin might be selectively altered before
epithelial cell damage in DSS‐induced colitis (Dharmani
et al, 2011), one of the most comprehensively tested models
of colitis that mimics the clinical and histological features of
human UC (Yan et al, 2009). The absence or inhibition of TNF
activity ameliorates disease progression in different experimen-Figure 7. Effect ofMMP13 on intestinal barrier dysfunction. LPS-induced shock
MMP13-mediated shedding of transmembrane-bound TNF and release of bioactive
secretion and eventually results in ER-stress, which leads to mucus depletion and
TNF induces caveolin-dependent endocytosis, resulting in destabilization of tigh
increased intestinal permeability (3). Consequent leakage of intestinal compone
eventually to death (4).
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.tal IBD models and in human patients. Treatment with a TNF
neutralizing antibody, a locally active TNF inhibitor, antisense
oligonucleotides and siRNA molecules speciﬁc for TNF were
shown to be effective in the DSS‐induced colitis model
(Dharmani et al, 2011; Murthy et al, 2002; Myers et al, 2003;
Ocampo et al, 2012). As expected, we observed that MMP13/
mice were less sensitive to DSS‐induced colitis than MMP13þ/þ
mice and that this was correlated with reduced bioactive TNF
levels. However, the protection was moderate, especially since
treatment with a TNF‐neutralizing antibody markedly reduces
the DSS‐induced clinical score (Dharmani et al, 2011). This can
be due to the fact that MMP13 is not the only important TNF
sheddase in this model or because other processes are also
involved. Indeed, the chemical DSS model is of great value for a
better understanding of acute inﬂammatory disease processes in
IBD, but during the recovery phase, also other processes such asand DSS-induced colitis result in MMP13 up-regulation in the gut. This leads to
, soluble TNF (1). Subsequently, sTNF induces goblet cell mucin expression and
increased interaction of bacteria with IECs and Paneth cells (2). Additionally,
t junctions. This is associated with loss of tight junction functionality and
nts increases systemic inflammation, which leads to organ damage and
EMBO Mol Med (2013) 5, 932–948
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to be delayed in MMP13/mice (Hartenstein et al, 2006). It has
been suggested that altered sensitivity of genetically modiﬁed
mice to DSSmust be viewed in the context of epithelial cell injury
and repair and should not be interpreted as a function of
disrupted tight junction permeability alone (Brown & Mayer,
2007; Williams et al, 2001).
Although we do not exclude that also other MMP13 substrates
play a role in the observed LPS resistance, we proved that the
observed phenotype is highly dependent on TNF activity.
Indeed, anti‐TNF treatment of endotoxemic mice resulted in
reduction of mortality, intestinal permeability and mucus
containing goblet cell loss and TNFR1/ mice were protected
against LPS‐induced lethality.
In conclusion (Fig 7), LPS‐induced shock and DSS‐induced
colitis induce MMP13 up‐regulation in the gut. This results in
MMP13‐mediated shedding of transmembrane‐bound TNF and
release of bioactive, soluble TNF. Subsequently, sTNF induces
mucin expression and secretion by goblet cells, and eventually
ER‐stress, which results in mucus depletion and increased
interaction of bacteria with IECs and Paneth cells. Additionally,
TNF induces caveolin‐dependent endocytosis, which destabil-
izes tight junctions. This causes loss of tight junction
functionality and increased intestinal permeability. Consequent
leakage of intestinal components increases systemic inﬂamma-
tion, which leads to organ damage and eventually to death.
Our results suggest that MMP13 is a potential therapeutic
target for treatment of inﬂammatory disorders associated with
TNF‐dependent dysfunction of the intestinal barrier, such as
sepsis and IBD. Unfortunately, the clinical use of pharmacologic
MMP inhibitors has been hampered by their lack of speciﬁcity
(Dorman et al, 2010). A major goal should be to identify
compounds targeting MMP13 without interfering with other
MMPs, not only for the previously suggested treatment of joint
diseases (Takaishi et al, 2008), but as shown by our data also for
the treatment of pathologies such as sepsis and IBD.MATERIALS AND METHODS
Animals
C57BL/6J MMP13/ mice (Inada et al, 2004) were housed in an SPF
animal facility with ad libitum access to food and water. We used both
male and femalemice (8–12weeks old). All experiments were approved
by the ethics committee of the Faculty of Science of Ghent University.
Endotoxemia model and TNF, pilocarpine and anti‐TNF
injections
Mice were injected intraperitoneally (i.p.) with LPS from Salmonella
enterica serotype abortus equi (Sigma; LD100 in MMP13
þ/þ mice:
17.5 mg/kg body weight) or with recombinant mouse TNF (LD100 in
MMP13þ/þmice: 1.25 mg/kg body weight) produced in Escherichia coli
and endotoxin‐free puriﬁed in our lab. In the experiments on
antibiotic‐treated mice, the mice were injected with 12.5 mg/kg LPS
intravenously (i.v.) instead of i.p. to avoid injection into the swollen
caecum. In the pilocarpine experiments, MMP13þ/þmice were injected
with 200 mg/kg pilocarpine 45 min prior to a sublethal LPS injectionEMBO Mol Med (2013) 5, 932–948 (i.p.; 6 mg/kg body weight). For MMP13/ mice, 17.5 mg/kg body
weight LPS (i.p.) was used. Control animals received injections of PBS.
Rectal bodytemperature was measured at different times after
challenge. Mice were bled by heart puncture, and serum or EDTA
plasma was prepared and stored at 20°C. Anti‐TNF (etanercept;
400 mg) was administered to the mice 30 min prior to LPS injection.
DSS model
Acute colitis was induced by addition of 2% DSS (dextran sulfate
sodium; 36–50 kD; MP Biomedicals) to the drinking water for 5 days.
Body weight, occult or gross blood lost per rectum, and stool
consistency were determined daily. Faecal blood was determined using
Hemoccult SENSA (Beckman Coulter) analysis. The baseline clinical
score was determined on day 0. No weight loss was scored as 0, weight
loss of 1–5% below baseline as 1, 5–10% as 2, 10–20% as 3, and
>20% as 4. For bleeding, a score of 0 was assigned for no blood, 2 for
positive Hemoccult, and 4 for gross bleeding. For stool consistency, a
score of 0 was assigned for well‐formed pellets, 2 for pasty stool, and 4
for liquid stool. These scores were combined and divided by three,
resulting in a total clinical score ranging from 0 (healthy) to 4 (maximal
colitis). To eliminate any diagnostic bias, mice were scored blindly.
Postmortem, the entire colon was removed from caecum to anus, its
length was measured as an indicator inﬂammation, and colon samples
were taken for RNA isolation, protein analysis and for preparing PFA‐
ﬁxed, parafﬁn‐embedded sections.
MMP13 inhibitor experiments
Four days after 4 ml of 3% thioglycollate injection, macrophages were
isolated by peritoneal lavage and two million cells were plated in six‐
well plates. Four hours later culture medium was refreshed and cells
were stimulated with LPS (100 ng/ml) in the absence or presence of
MMP13 inhibitor (1 nM; Calbiochem) and medium was collected after
different time points. For the explant experiments, mice were injected
with LPS (17.5 mg/kg) and ileum was harvested 15 min later. Flushed
ileum pieces of 1.5 cm were incubated ex vivo in the presence or
absence of different concentrations MMP13 inhibitor (10 nM and
100 nM; Calbiochem).
Caecal ligation and puncture model
Severe sepsis was induced in isoﬂurane anesthetizedmice by ligation of
the cecum, followed by twice puncturing with a 21‐gauge needle as
described earlier (Rittirsch et al, 2009). All animals received two doses
of antibiotic therapy i.p. (ceftriaxone 25 mg/kg and metronidazole
12.5 mg/kg) at 9 and 24 h after CLP.
Depletion of commensal intestinal bacteria
For antibiotic‐mediated depletion of commensal bacteria, the drinking
water was supplementedwith 200 mg/L ciproﬂoxacin (Sigma–Aldrich),
1 g/L ampicillin (Sigma–Aldrich), 1 g/L metronidazole (Sigma–Aldrich)
and 500 mg/L vancomycin (Labconsult). After 2 weeks, the presence of
colonic microﬂora was determined by culturing faecal samples in brain
heart infusion (BD Biosciences) and in thioglycollate medium (Sigma–
Aldrich).
Real time qPCR
Organs were stored in RNALater (Ambion) and RNA was isolated by
using the RNeasy Mini Kit (Qiagen). cDNA was synthesized by the2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 943
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944iScript cDNA Synthesis Kit (BioRad). Real time PCR was performed on
the Light Cycler 480 system (Roche) using the LightCycler 480 SYBR
Green I Master (Roche). Expression levels were normalized to the
expression of the two most stable housekeeping genes, which were
determined for each organ using the geNorm Housekeeping Gene
Selection Software (Vandesompele et al, 2002).
Cytokine/chemokine measurements
Quantiﬁcation of cytokines and chemokines (in pg/ml) in serum was
performed using the Bio‐Plex cytokine assays (Bio‐Rad), according to
the manufacturer’s instructions. TNF bioactivity (in U/mg tissue) was
determined by using the L929 bioassay system.
Intestinal permeability
FITC‐labeled dextran (4 kDa, Sigma) was administered to mice by
gavage at 150 mg/kg body weight. Five hours later, blood obtained by
heart puncture was collected in EDTA‐coated tubes (Sarstedt) and
plasma was prepared. Leakage of FITC‐labeled dextran into the
circulation was determined by measurement of the plasma ﬂuores-
cence (lex/lem ¼ 488/520 nm). Values were normalized to the lowest
value.
Histopathology of small intestine
Tissues were ﬁxed with 4% PFA, embedded in parafﬁn, sectioned at
4 mm, dewaxed and stained. After hematoxylin (Fluka) and eosin
(Merck) staining, sections were mounted and the degree of damage
was evaluated on entire organ sections by four neutral observers in a
blinded fashion. Intestinal damage is characterized by decreased villus
height, epithelial cell death at the villus top, and loss of mucus layer
and goblet cells. Taking into account all histological features, a damage
score ranging from 0 (normal) to 4 (abnormal) was given to each
mouse. Alcian blue staining was performed by incubating the ileum
sections for 30 min in 0.1% Alcian blue, followed by two washing steps
and counterstaining with nuclear fast red for 5 min. Finally, sections
were rehydrated and mounted. The amount and size distribution of
Alcian blue positive goblet cells was measured automatically by using
the Volocity software (Perkin–Elmer).
Immunostaining
Tissues were ﬁxed with 4% PFA, embedded in parafﬁn, sectioned at
4 mm, dewaxed and stained. For immunoﬂuorescent labelling, sections
were boiled in 10 mM sodium citrate buffer for antigen retrieval,
incubated for 1 h in blocking buffer (10 mM Tris–HCl pH 7.4, 0.1 M
MgCl2, 0.5% Tween20, 1% BSA and 5% serum), and incubated
overnight with anti‐BiP (1/40; C50B12, Cell signaling) or anti‐MUC2
antibody (1/200; sc‐15334, Santa Cruz). After rinsing with TBS/0.1%
Tween‐20, sections were incubated with ﬂuorescently labeled
secondary antibody DAR555 (1/400; Invitrogen). After another
washing step, sections were counterstained with DAPI and mounted.
Fluorescent images were taken by a laser scanning confocal
microscope (Leica TCS SP5).
Transmission electron microscopy (TEM)
The excised ileum was ﬁxed in a solution of glutaraldehyde and
formaldehyde (0.3%/2.5% for morphological EM analysis and 2.5%/4%
immune‐EM (IEM)) dissolved in 0.1 M sodium cacodylate buffer
containing 20 mg/100 ml CaCl2. Fixed specimens were dehydrated 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.through a graded ethanol series and embedded in Spurr’s resin for
morphological EM analysis or in LR White’s resin for IEM. Ultrathin
sections of a gold interference colour were cut using an ultramicrotome
(Leica EM UC6) and sections were collected on formvar‐coated copper
slot grids. For IEM, grids were incubated with blocking solution (5%
BSA, 1% FSG in PBS) for 20 min, followed by thorough washing with
PBS/1% BSA. Next, sections were incubated for 2 h with anti‐ZO‐1 (1/
5; 617300, Life Technologies) diluted in PBS/1% BSA. After another
washing step, grids were incubated for 30 min with protein A‐10‐nm
gold (PAG10nm; Cell Biology Department, Utrecht University) and with
PBS/0.1% BSA, PBS, and double‐distilled water. Control experiments
consisted of treating sections with PAG10nm alone. Finally, sections
were post‐stained with uranyl acetate for 40 min and lead citrate for
7 min in a Leica EM AC20 and viewed with a transmission electron
microscope (JEOL 1010; JEOL, Tokyo, Japan).
Tight junction protein analysis
The excised ileum was washed with ice‐cold PBS, cut open
longitudinally, and mucosal samples were obtained by scraping to
enrich for villi. Mucosal scrapings were homogenized in lysis buffer
(50 mMTris, 25 mM KCl, 5 mMMgCl2.6H2O, 2 mMEDTA, 40 mMNaF,
4 mM Na3VO4, pH 7.4) containing 1% Triton X‐100 and a protease
inhibitor mixture solution. For total protein analysis, samples were
centrifuged for 15 min at maximal speed and supernatant was
collected. Tight junction membrane microdomains were isolated
according to a previously described method (Li et al, 2008). The
homogenized samples were mixed with an equal volume of 80%
sucrose in lysis buffer and loaded at the bottom of an ultracentrifuge
tube. A discontinuous sucrose gradient was layered on top of the
sample by layering 30, 25, 20 and 5% sucrose (2 ml each). The
gradients were ultracentrifuged (250,000 g, 18 h at 4°C) in a Ti90
rotor in an Optima L‐80XP ultracentrifuge (Beckman). Ten 1‐ml
fractions were collected from the top of each tube. Protein
concentration was determined by BCA assay (Pierce) and samples
were analysed by Western blot analysis. Blots were incubated
overnight with anti‐actin (1/10,000; 691002, MP Biomedicals),
anti‐claudin‐1 (1/5000; 519000, Life Technologies), anti‐occludin
(1/250; 422400, Life Technologies), anti‐ZO‐1 (1/1000; 617300, Life
Technologies) or anti‐caveolin (1/500; ab2910, AbCam) antibody
overnight at 4°C, followed by 1 h incubation with IRDye antibody
(1/10,000; Westburg) at room temperature. Immunoreactive proteins
were visualized and quantiﬁed using the Odyssey™ Infrared Imaging
System and Odyssey software as described by the manufacturer
(Li‐Cor).
Cell culture
HT29‐MTX goblet cells were a kind gift from Dr. Thécla Lesufﬂeur
(INSERM UMR S 938, Paris, France) (Lesufﬂeur et al, 1993) and were
grown in DMEM supplemented with 25 mM glucose and 10% FBS.
Cells were seeded in six‐well plates and 21 days later, 2000 U/ml
recombinant human TNF was added and samples were collected at
different times, followed by RNA isolation. Recombinant human TNF
was produced in E. coli and endotoxin‐free puriﬁed.
Quantiﬁcation of total goblet cell mucus
(Kitagawa et al, 1986). The excised ileum was soaked for 2 h in 2 ml of
0.1% Alcian blue, dissolved in 0.16 M sucrose buffered with 0.05 MEMBO Mol Med (2013) 5, 932–948
The paper explained
PROBLEM:
Sepsis is a highly mortal, inflammatory disease initiated by an
infection and associated with systemic inflammation and organ
dysfunction. The prevalence is high and current treatments are
ineffective and mainly supportive. MMPs are important
inflammatory mediators during sepsis, as well as inflammation
at the level of the gut, but the link between these two has not
been clearly established.
RESULTS:
We found thatmice deficient for the collagenaseMMP13 strongly
resist sepsis and are protected against sepsis-induced gut
permeability, goblet cell depletion, as well as induction of ER
stress and tight junctions dysfunction in the small intestine.
In vitro and in vivo experiments revealed that MMP13 is able to
cleave membrane bound TNF, which is the initiator of the
observed intestinal inflammation. Similarly, we also revealed a
detrimental role forMMP13 in the TNF-dependent disease colitis.
IMPACT:
We propose MMP13 as a novel drug target for diseases in which
TNF-induced damage to the gut is essential, such as sepsis and
colitis.
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successive washes in 2 ml of 0.25 M sucrose for 15 and 45 min. Next,
the mucus‐complexed dye was extracted by treatment with laxative
(30% disodium octyl sulfosuccinate) for 2 h. After centrifugation
(3000 rpm for 10 min), the optical density of the extracted solution
was read at 620 nm and the concentration of the extracted Alcian blue
was calculated in comparison with a calibration curve obtained from
known concentrations of Alcian blue solutions.
IL‐FABP ELISA
Concentrations of ileal fatty acid binding protein in plasma were
determined by a standard enzyme‐linked immunosorbent assay (ELISA)
for mouse IL‐FABP according to manufacturer’s instructions (Hycult
Biotechnology).
LDH activity
LDH activity in plasma was measured by the CytoTox 96 Assay
(Promega), according the manufacturer’s instructions.
ProTNF cleavage assay
Recombinant MMP13 (511‐MM‐010, R&D) was diluted to 100 mg/ml
in assay buffer (50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij‐
35, pH 7.5) and activated by incubation for 2 h at 37°C in the presence
of 1 mM APMA. Recombinant proTNF fusion protein (1012‐PS‐010,
R&D systems) was diluted in 50 mM Tris pH 8 at a concentration of
200 mg/ml. ProTNF was incubated with activated MMP13 at 37°C in a
1:1 ratio (w:w) and samples were taken at different times points.
Reaction was stopped by addition of loading buffer followed by snap
freezing. As a control for self‐cleavage, proTNF and activated MMP13
samples were treated similarly, but without co‐incubation. Equal
amounts of sample were loaded on a 15% SDS–PAGE. Control samples
(proTNF and MMP13 alone) were visualized by silver staining. Samples
of co‐incubated proTNF and MMP13 were analysed by western blot.
Blots were incubated overnight with anti‐TNF antibody (1/1000;
SAB4502982, Sigma–Aldrich) followed by 1 h incubation with IRDye
800CWgoat anti‐rabbit IgG antibody (1/10,000) at room temperature.
Immunoreactive proteins were visualized using the Odyssey™ InfraredEMBO Mol Med (2013) 5, 932–948 Imaging System and Odyssey software as described by the
manufacturer (Li‐Cor).
In‐gel stable‐isotope labelling and LC‐MS/MS analysis
(Asara et al, 2006). The gel bands containing full length and possible
TNF fragments upon cleavage by MMP13 were excised from the
coommassie‐stained SDS–PAGE and washed consecutively with water
(Milli‐Q puriﬁed, Millipore), water/acetonitrile (1/1, with acetonitrile
HPLC grad; Biosolve) and acetonitrile, each for 15 min. After these
washing steps, the gel bands were vacuum dried. Each gel band was
then re‐swollen in 1 mg NHS‐trideutero‐acetate (synthesized in‐house
according to (Staes et al, 2011)) dissolved in 100 ml 50 mM
triethylammonium bicarbonate (Sigma–Aldrich) pH 8. Trideutero‐
acetylation of primary amines, i.e., e‐amines of lysines and a‐amines of
free (neo)N‐termini, was allowed for 1 h at 30°C, followed by washing
the gel bands again with water followed by acetonitrile, each for
15 min and vacuum dried. These trideutero‐acetylation and washing
steps were once repeated in order to reach maximal trideutero‐
acetylation. Subsequent washing the gel bands with 50 mM
ammonium bicarbonate (Sigma–Aldrich) quenches any remaining
NHS‐ester, after which the gel bands were vacuum dried. Hydroxyl-
amine (2 ml, 50 wt%; Sigma–Aldrich) in 100 ml 50 mM ammonium
bicarbonate was added to each gel band for 20 min at 30°C in
order to reverse possible O‐trideutero‐acetylation of Ser, Thr and Tyr.
Samples were washed consecutively for 15 min with 50 mM
ammonium bicarbonate and acetonitrile and vacuum dried. Each
gel band was re‐swollen with 10 ml 50 ng sequence grade trypsin
(Promega Corporation). Gel bands were completely immersed in
50 mM ammonium bicarbonate and trypsin digestion was allowed
overnight at 37°C. Two microliters of 100% formic acid was added to
deactivate trypsin, the peptide mixtures were vacuum dried and re‐
dissolved in 20 ml of 0.1% triﬂuoroacetic acid (Biosolve) in 2%
acetonitrile.
The peptide mixtures were then introduced into an LC‐MS/MS
system, the Ultimate 3000 RSLC nano (Dionex) in‐line connected to an
LTQ Orbitrap Velos (Thermo Fisher Scientiﬁc) for peptide identiﬁcation.
Sample mixture (2.5 ml) was loaded on a trapping column (made2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 945
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946in‐house, 100 mm internal diameter (I.D.)  20 mm length, 5 mmC18
Reprosil‐HD beads; Dr. Maisch). After ﬂushing from the trapping
column, the sample was loaded on a reverse‐phase column (made in‐
house, 75 mm ID  150 mm, 5 mm C18 Reprosil‐HD beads;
Dr. Maisch). Peptides were separated with a 30 min linear gradient
from 2% solvent A (0.1% formic acid) to 50% solvent B (0.1% formic
acid in 80% acetonitrile) at a ﬂow rate of 300 nl/min followed by a
wash with solvent B.
The mass spectrometer was operated in data‐dependent mode,
automatically switching between MS and MS/MS acquisition for the 10
most abundant peaks in a MS spectrum. Full scan MS spectra were
acquired in the Orbitrap at a target value of 1E6 with a resolution of
60,000. The 10 most intense ions were isolated for fragmentation in the
linear ion trap, with a dynamic exclusion of 20 s and fragmented
after ﬁlling the ion trap at a target value of 1E4 ion counts. From theMS/
MS data in each LC run, Mascot Generic Files were created using the
Distiller software (version 2.4.2.0, Matrix Science, www.matrixscience.
com/Distiller).These peak lists were then searchedwith theMascot search
engine (Matrix Science) using the Mascot Daemon interface (version 2.3,
Matrix Science). Spectra were searched against the Swiss‐Prot database
(version 2012_05 of the UniProtKB/Swiss‐Prot protein database)
restricted to human proteins concatenated with the TNFa part of the
fusion protein. Variable modiﬁcations were set to methionine oxidation,
pyro‐glutamate formation of N‐terminal glutamine, S‐propionamide
formation of cysteines, acetylation of the peptide N‐terminus and tri‐
deuteroacetylation of the peptide N‐terminus. Fixed modiﬁcations
were set to tri‐deuteroacetylation on lysine. Mass tolerance on peptide
ionswas set to 10 ppm (withMascot’s C13 option set to 1), and to 0.5 Da
for peptide fragment ions. The peptide charge was set to 1þ, 2þ, 3þ and
instrument setting was put on ESI‐TRAP. Enzyme was set to semi‐ArgC/P,
allowing for 1 missed cleavage, and cleavage was also allowed when
arginine is followed by proline. Only peptides that were ranked one
and scored above the threshold score, set at 99% conﬁdence, were
withheld. All further data management was done by ms_lims (Helsens
et al, 2010).
Statistical analysis
Data are presented as means  SEM. Data were analysed with an
unpaired Mann–Whitney U‐test, unless mentioned differently. Survival
curves were compared using a log‐rank test. Signiﬁcances were
calculated for differences from the corresponding 0 h time point and/or
between MMP13þ/þ and MMP13/ mice, as indicated (, 0.01  p
< 0.05; , 0.001  p < 0.01; , p < 0.001).Author contributions
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